Revolutionary change in rheumatoid arthritis management with biological therapy

Keio Journal of Medicine

Volumn 60, Issue 3, 2011, Pages 75-81

  Takeuchi, Tsutomu ^a  

^a School of Medicine   (Japan)

Author keywords

IL 6; Remission; Safety; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; LYMPHOTOXIN; MONOCLONAL ANTIBODY; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; BIOLOGICAL THERAPY; DRUG APPROVAL; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; JAPAN; MULTICENTER STUDY (TOPIC); PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856073008     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.60.75     Document Type: Review

References (33)

1. Elliott MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-1690. [Medline] [CrossRef].
2. Elliott MJ, Maini RN, Feldmann M, et al: Randomised double- blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110. [Medline] [CrossRef].
3. Takeuchi T, Kameda H: The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010; 6: 644-652. [Medline] [CrossRef].
4. Mitoma H, Horiuchi T, Tsukamoto H, et al: Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-1257. [Medline] [CrossRef].
5. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I: A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low-dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 2006; 33: 37-44. [Medline].
6. Nishimoto N, Yoshizaki K, Miyasaka N: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769. [Medline] [CrossRef].
7. Miyasaka N, Investigators TC: Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008; 18: 252-262. [Medline] [CrossRef].
8. Yamanaka H, Tanaka Y, Sekiguchi N, et al: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 2007; 17: 28-32. [Medline] [CrossRef].
9. Tanaka Y, Takeuchi T, Inoue E, et al: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical and radiographic outcomes (RECONFIRM-II). Mod Rheumatol 2008; 18: 146-152. [Medline] [CrossRef].
10. Takeuchi T, Yamanaka H, Inoue E, et al: Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2 J). Mod Rheumatol 2008; 18: 447-454. [Medline] [CrossRef].
11. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, Takeuchi T: Fc gamma receptor IIIb polymorphism and usage of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 299-304. [Medline] [CrossRef].
12. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T: Impact of trough serum level on radiographic and clinical response to infli - imab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009; 19: 478-487. [Medline] [CrossRef].
13. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T: Baseline TNF-alpha levels predict clinical response to infliximab for patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1208-1215.
14. Kameda, H., Y. Ueki, K. Saito, et al: Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: A randomized trial. Mod Rheum 2011; 20: 531-538. [CrossRef].
15. Kameda H, Kanbe K, Sato E, et al: Etanercept (ETN) plus methotrexate (MTX) combination therapy resulted in a better outcome in joint damage and physical function than ETN monotherapy even in patients with active rheumatoid arthritis despite MTX treatment: 52-week results from the JESMR study. J Rheum 2011; doi:10.3899/jheum.1100.
16. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T: Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-19. [Medline] [CrossRef].
17. Yamanaka H, Tanaka Y, Inoue E, et al: Efficacy of tocilizumab in rheumatoid arthritis patients with daily clinical practice in Japan: Results from a retrospective study (REACTION). Mod Rheum 2011; 21: 122-133.
18. Takeuchi T, Tanaka Y, Amano K, et al: Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011; doi: 10.1093/rheumatology/ker221.
19. Nishimoto N, Hashimoto J, Miyasaka N, et al: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167. [Medline] [CrossRef].
20. Lipsky PE, van der Heijde DM, St Clair EW, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602. [Medline] [CrossRef].
21. Takeuchi T, Tatsuki Y, Nogami Y, et al: Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-194. [Medline] [CrossRef].
22. Koike T, Harigai M, Inokuma S, et al: Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36: 898-906. [Medline] [CrossRef].
23. Takeuchi T, Kawai S, Yamamoto K, Miyasaka N: Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69(Suppl 3): 219.
24. Tokuda H, Sakai F, Yamada H, et al: Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008; 47: 915-923. [Medline] [CrossRef].
25. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, Ishizaka A: Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131: 1173-1180. [Medline] [CrossRef].
26. Quinn MA, Conaghan PG, O'Connor PJ, et al: Very early treatment with infliximab in addition to methotrexate in early, poorprognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35. [Medline] [CrossRef].
27. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al: Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 914-921. [Medline] [CrossRef].
28. Tanaka Y, Takeuchi T, Mimori T, et al: Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286-1291. [Medline] [CrossRef].
29. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52: 2693-2696. [Medline] [CrossRef].
30. Canete JD, Suarez B, Hernandez MV, et al: Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1547-1552. [Medline] [CrossRef].
31. Sekiguchi N, Kawauchi S, Furuya T, et al: Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47: 780-788. [Medline] [CrossRef].
32. Tanino M, Matoba R, Nakamura S, et al: Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun 2009; 387: 261-265. [Medline] [CrossRef].
33. Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun 2004; 5: 641-647. [Medline] [CrossRef].